

Lipodystrophy Therapeutic Pipeline Market Review, H2 2016


Lipodystrophy Global Market 2016 Analysis and Forecast to 2021

PUNE, INDIA, September 26, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Lipodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lipodystrophy and features dormant and discontinued projects.

Complete Report @

https://www.wiseguyreports.com/reports/649790-lipodystrophy-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly



The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
- The report reviews pipeline therapeutics for Lipodystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lipodystrophy therapeutics and enlists all their major and



minor projects

- The report assesses Lipodystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lipodystrophy

Get Sample Report @ https://www.wiseguyreports.com/sample-request/649790-lipodystrophy-pipeline-review-h2-2016

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ https://www.wiseguyreports.com/enquiry/649790-lipodystrophy-pipeline-review-h2-2016

Table of Content

Lipodystrophy Overview 6

Therapeutics Development 7

Pipeline Products for Lipodystrophy - Overview 7

Lipodystrophy - Therapeutics under Development by Companies 8

Lipodystrophy - Pipeline Products Glance 9

Late Stage Products 9

Early Stage Products 10

Lipodystrophy - Products under Development by Companies 11

Lipodystrophy - Companies Involved in Therapeutics Development 12

Aegerion Pharmaceuticals, Inc. 12

Akcea Therapeutics Inc 13

Ambrx, Inc. 14

Amunix Operating Inc. 15

Bolder Biotechnology, Inc. 16

Lipodystrophy - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 23

Drug Profiles 25

AMX-342 - Drug Profile 25 **Product Description 25** Mechanism Of Action 25 R&D Progress 25 ARX-328 - Drug Profile 26 **Product Description 26** Mechanism Of Action 26 R&D Progress 26 BBT-031 - Drug Profile 27 **Product Description 27** Mechanism Of Action 27 R&D Progress 27 metreleptin - Drug Profile 28 **Product Description 28** Mechanism Of Action 28 R&D Progress 28 volanesorsen sodium - Drug Profile 33 **Product Description 33** Mechanism Of Action 33 R&D Progress 33

Buy now @ https://www.wiseguyreports.com/checkout?currency=one user-USD&report id=649790 Continued...

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.